Co-Diagnostics (Nasdaq:CODX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CODX 주식 개요

는 분자 진단 회사로, 핵산 분자의 검출 및/또는 분석을 통해 작동하는 진단 테스트에 사용되는 시약을 개발, 제조 및 판매하며 미국 및 국제적으로 판매하고 있습니다.

CODX 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

위험 분석

최근 3개월간 주가 변동폭 심해

수익은 향후 3년간 연평균 5.1% 씩 감소할 것으로 예상됩니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $48M )

Co-Diagnostics, Inc. 경쟁사

Talis Biomedical

NasdaqCM:TLIS

US$15.9m

Eargo

NasdaqGS:EAR

US$53.4m

Owlet

NYSE:OWLT

US$39.4m

Cytosorbents

NasdaqCM:CTSO

US$42.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Co-Diagnostics
과거 주가
현재 주가	US$1.47
52주 최고치	US$1.89
52주 최저치	US$0.98
베타	-0.85
11개월 변경	34.86%
3개월 변경 사항	24.58%
1년 변경 사항	33.64%
33년 변화	-82.83%
5년 변화	82.84%
IPO 이후 변화	-74.70%

최근 뉴스 및 업데이트

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Jun 14

Recent updates

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Jun 14

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14

Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test

Jun 18

Co-Diagnostics: No One-Hit Wonder

Jun 04

This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year

May 18

주주 수익률

	CODX	US Medical Equipment	US 마켓
7D	-7.5%	0.4%	0.4%
1Y	33.6%	-0.6%	22.9%

수익률 대 산업: CODX 지난 1년 동안 -0.5 %를 반환한 US Medical Equipment 산업을 초과했습니다.

수익률 대 시장: CODX 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is CODX's price volatile compared to industry and market?
CODX volatility
CODX Average Weekly Movement	15.7%
Medical Equipment Industry Average Movement	7.7%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: CODX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: CODX 의 주간 변동성( 16% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2013	155	Dwight Egan	www.codiagnostics.com

분자 진단 회사인 코-디그노스틱스는 핵산 분자의 검출 및/또는 분석을 통해 작동하는 진단 테스트에 사용되는 시약을 개발, 제조 및 판매하며 미국 및 국제적으로 판매하고 있습니다. 이 회사는 현장 진료 및 재택 환경에서 환자를 대상으로 중합효소 연쇄 반응(PCR) 검사인 Co-Dx PCR 플랫폼을 제공합니다. 또한 코로나19, 인플루엔자, 결핵, B형 및 C형 간염, 인유두종 바이러스, 말라리아, 치쿤구니야, 뎅기열, 지카 바이러스에 대한 PCR 진단 테스트도 제공합니다.

Co-Diagnostics, Inc. 기본 사항 요약

Co-Diagnostics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CODX 기본 통계
시가총액	US$45.35m
수익(TTM)	-US$38.89m
수익(TTM)	US$6.68m

6.9x

P/S 비율

-1.2x

P/E 비율

CODX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CODX 손익 계산서(TTM)
수익	US$6.68m
수익 비용	US$3.92m
총 이익	US$2.76m
기타 비용	US$41.65m
수익	-US$38.89m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.24
총 마진	41.34%
순이익 마진	-582.36%
부채/자본 비율	0%

CODX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CODX 주식 개요

보상

위험 분석

Co-Diagnostics, Inc. 경쟁사

NasdaqCM:TLIS

US$15.9m

NasdaqGS:EAR

US$53.4m

NYSE:OWLT

US$39.4m

NasdaqCM:CTSO

US$42.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Recent updates

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Chairman exercised options and sold US$58k worth of stock

Consensus revenue estimates increase by 474%

Price target increased by 50% to US$3.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Consensus revenue estimates fall by 43%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Consensus revenue estimates fall by 83%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Chairman exercised options and sold US$111k worth of stock

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Co-Diagnostics: Hold Thesis Remains Well Intact

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Price target decreased to US$15.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Co-Diagnostics spikes on shipments of monkeypox test

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Now 24% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Chairman exercised options and sold US$59k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to US$19.33

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week